Which pharmaceutical company has the most SPC in Norway? – DrugPatentWatch
This chart shows the pharmaceutical companies with the most additional protection certificates (SPCs) in Norway.
SPC is used in the European Union and select others to drive pharmaceutical innovation
compensation for the long time it took to get regulatory approval for the drugs. SPC
enters into force only after the corresponding general patent expires, and usually has a maximum life span of 5 years.
The combined total duration of market exclusivity of general patents and SPCs cannot normally exceed 15 years, but is extended by six months
can be obtained by responding to a request for a pediatric trial.
For a different perspective, look at the drug companies with SPCs in most countries
The pharmaceutical companies with the most SPCs in Norway are:
- Gilead Sciences Inc
- Msd Merck Co
- Abbvie Inc
- Novartis
- Astrazeneca
- Pfizer
- Alnylam
- Bayers Health
- Boehringer Ingelheim
- Bristol
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Make Better Decisions with DrugPatentWatch
» Start Your Free Trial Today «
Copyright © DrugPatentWatch. Originally published in Which pharmaceutical company has the most SPC in Norway?
